An Investigation of the Characteristics of a Negative Pion Beam by Means of Induced Chromosome Aberrations in Human Peripheral Blood Lymphocytes

Summary The depth dose profiles of unstable chromosome aberrations were determined by irradiating blood samples at various depths in a plastic phantom exposed to a beam of negative π mesons (pions). The pions were derived from an experimental beam line from the Nimrod 7 GeV proton synchrotron. With...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Int. J. Radiat. Biol., v. 27, no. 3, pp. 223-236 v. 27, no. 3, pp. 223-236, 1975-01, Vol.27 (3), p.223-236
Hauptverfasser: Lloyd, D.C., Purrott, R.J., Dolphin, G.W., Reading, D.H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary The depth dose profiles of unstable chromosome aberrations were determined by irradiating blood samples at various depths in a plastic phantom exposed to a beam of negative π mesons (pions). The pions were derived from an experimental beam line from the Nimrod 7 GeV proton synchrotron. With a momentum of 160 MeV/c and a spread of 15 per cent a Bragg profile was produced peaking at 13·9 cm. An ionization peak to plateau ratio of 1·6 was obtained and for cytogenetic damage this was increased to 2·9. Dicentric and acentric dose-response data from peak and plateau positions were fitted to Y = αD + βD2 models for comparison with data obtained from 60Co gamma-rays and fission neutrons. With respect to 150 rads gamma-radiation, the r.b.e. values for the pion peak were 2·1 for dicentrics and 2·3 for acentrics. In the plateau the value for both aberrations was 1·5. At pion doses likely to be used as daily radiotherapy fractions, the aberrations predominantly resulted from single-track events, indicating little likelihood of interfraction recovery, particularly in the peak position. It is concluded that the biological damage characteristics of pion beams, as determined from a cytogenetic end-point, offer several features attractive to the radiotherapist.
ISSN:0955-3002
0020-7616
1362-3095
DOI:10.1080/09553007514551521